We are live on ! Find out more
KAPA

Kairos Pharma
KAPA

11 hedge funds and large institutions have $342K invested in Kairos Pharma in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

1.22% less ownership

Funds ownership: 4.11% → 2.89% (-1.2%)

21% less funds holding

Funds holding: 14 → 11 (-3)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

44% less capital invested

Capital invested by funds: $607K → $342K (-$266K)

Holders
11
Holders Change
-3
Holders Change %
-21.43%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$25.8K
2
TSS
Two Sigma Securities
New York
+$10.9K
3
HF
HRT Financial
New York
+$171
4
Citigroup
Citigroup
New York
+$7

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$228K
2
Two Sigma Investments
Two Sigma Investments
New York
-$36.5K
3
XT
XTX Topco
Cayman Islands
-$34.4K
4
VF
Virtu Financial
New York
-$14K
5
Osaic Holdings
Osaic Holdings
Arizona
-$9.26K
Name Holding Trade Value Shares
Change 		Change in
Stake
VCM
1
Vanguard Capital Management
Pennsylvania
$130K +$155K +231,878 New
Geode Capital Management
2
Geode Capital Management
Massachusetts
$62.2K +$25.8K +38,457 +53%
VFT
3
Vanguard Fiduciary Trust
Pennsylvania
$35.7K +$42.8K +63,884 New
SFG
4
SevenBridge Financial Group
Pennsylvania
$30.3K – – –
ACA
5
Aptus Capital Advisors
Alabama
$24.8K – – –
Two Sigma Investments
6
Two Sigma Investments
New York
$22.1K -$36.5K -54,465 -58%
State Street
7
State Street
Massachusetts
$13.5K – – –
HF
8
HRT Financial
New York
$12K +$171 +256 +1%
TSS
9
Two Sigma Securities
New York
$9.08K +$10.9K +16,247 New
TRCT
10
Tower Research Capital (TRC)
New York
$2.21K -$178 -265 -6%
Citigroup
11
Citigroup
New York
$6 +$7 +10 New
Citadel Advisors
12
Citadel Advisors
Florida
– -$228K -321,738 Closed
XT
13
XTX Topco
Cayman Islands
– -$34.4K -48,494 Closed
VF
14
Virtu Financial
New York
– -$14K -20,278 Closed
Two Sigma Advisers
15
Two Sigma Advisers
New York
– -$10.8K -15,142 Closed
Osaic Holdings
16
Osaic Holdings
Arizona
– -$9.26K -13,045 Closed
Bank of America
17
Bank of America
North Carolina
– -$95 -134 Closed

KAPA Hedge Fund Activity: Q1 2026 in Review

11 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Kairos Pharma (KAPA) for Q1 2026, worth a combined $342K — down 44% from $607K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of KAPA and 4 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, adding an estimated $25.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $228K sold.

  • 11 institutional investors held Kairos Pharma (KAPA) as of Q1 2026, down from 14 in Q4 2025.
  • Funds reported $342K of Kairos Pharma stock for Q1 2026, down 44% quarter-over-quarter.
  • 4 funds opened new Kairos Pharma positions in Q1 2026 and 6 closed out, a net change of -2 holders.
  • The largest Kairos Pharma buyer in Q1 2026 was Geode Capital Management, an estimated $25.8K added.
  • The largest Kairos Pharma seller in Q1 2026 was Citadel Advisors, an estimated $228K sold.

Based on aggregated 13F filings for Q1 2026.